Skip to content
Study details
Enrolling now

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Iovance Biotherapeutics, Inc.
NCT IDNCT07288203ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 8.1 years

Ages

18–70

Locations

1 site in TN

What this study is about

This trial is testing a treatment called lifileucel, which are tumor-infiltrating lymphocytes (TILs), in adults with advanced melanoma. This is a Phase 2 trial for participants who have previously received treatment for unresectable or metastatic melanoma.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Lifileucel

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lifileucel

Endpoints

Primary: Objective Response Rate

Secondary: Adverse Events, Complete Response Rate, Disease Control Rate, Duration of Response, Objective Response Rate, Overall Survival, Progression-Free Survival

Body systems

Oncology